Search

Your search keyword '"Franek E"' showing total 352 results

Search Constraints

Start Over You searched for: Author "Franek E" Remove constraint Author: "Franek E"
352 results on '"Franek E"'

Search Results

1. Atherosclerosis Risk Factors in Patients with Reactive Hypoglycemia

8. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

19. Effects of Alirocumab on Cardiovascular Events After Coronary Bypass Surgery

20. Effect of Alirocumab on Mortality After Acute Coronary Syndromes An Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial

21. Alirocumab Reduces Total Hospitalizations and Increases Days Alive and Out of Hospital in the ODYSSEY OUTCOMES Trial

23. Liraglutide and Renal Outcomes in Type 2 Diabetes

24. Vergleich der kardiovaskulären Sicherheit und des Auftretens schwerer Hypoglykämien mit Insulin degludec vs. Insulin glargin 100 E/ml bei älteren Patienten (≥65 Jahre) mit Typ 2 Diabetes: Beobachtungen aus DEVOTE

27. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management

28. Étude LEADER - liraglutide et événements cardiovasculaires : analyse complémentaire chez les sujets âgés ≥ 75 ans

31. LEADER-4: blood pressure control in patients with type 2 diabetes and high cardiovascular risk: baseline data from the LEADER randomized trial

32. LEADER 5 : prevalence and cardiometabolic impact of obesity in cardiovascular high-risk patients with type 2 diabetes mellitus: baseline global data from the LEADER trial

35. Schnell wirksames Insulin aspart (Faster aspart) vs. Insulin aspart zur Mahlzeit im Rahmen einer Basal-Bolus-Behandlung verbesserte die Blutzuckereinstellung bei T1D: die doppelblinde onset® 1-Studie

36. L’insuline Faster Aspart vs insuline asparte en prandiale en double aveugle améliore le contrôle glycémique chez le DT1 : étude onset ® 1

39. L’insuline asparte ultra-rapide vs insuline asparte en prandiale améliore le contrôle glycémique chez les patients DT1 : étude onset® 1

48. Safety and efficacy of insulin degludec/insulin aspart with bolus mealtime insulin aspart compared with standard basal-bolus treatment in people with Type 1 diabetes: 1-year results from a randomized clinical trial ( BOOST® T1).

49. SAT0463 Effect of Eight Years of Denosumab Treatment in Postmenopausal Women with Osteoporosis: Five-Year Results from the Freedom Extension

50. Efficacité et tolérance de l’insuline dégludec administrée selon un schéma flexible versus insuline dégludec ou insuline glargine administrées selon un schéma fixe dans le diabète de type 1 : résultats de l’essai « BEGIN: Flex T1 », un essai randomisé en treat-to-target de 26 semaines, et de son extension à 52 semaines

Catalog

Books, media, physical & digital resources